Clinical trial of pemetrexed injection combined with carboplatin injection in the treatment of advanced lung adenocarcinoma with epidermal growth factor receptor-tyrosine kinase inhibitor resistance
10.13699/j.cnki.1001-6821.2018.19.006
- VernacularTitle:培美曲塞注射剂联合卡铂注射液治疗表皮生长因子受体-酪氨酸激酶抑制药耐药后晚期肺腺癌患者的临床研究
- Author:
Wei-Ping ZHANG
1
;
Hai-Feng YING
;
Kuang-Zhang YOU
;
Ru-Yi HE
Author Information
1. 恩泽医疗中心集团 浙江省台州医院老年医学科
- Keywords:
pemetrexed injection;
carboplatin injection;
epidermal growth factor receptor -tyrosine kinase inhibitor;
advanced lung adenocarcinoma;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(19):2262-2265
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of pemetrexed injection combined with carboplatin injection in the treatment of advanced lung adenocarcinoma with epidermal growth factor receptor -tyrosine kinase inhibitor ( EGFR-TKI) resistance.Methods Eighty-four patients of advanced lung adenocarcinoma after EGFR -TKI resis-tance were divided into control and treatment groups with 42 cases per group.Control group received 500 mg· m-2pemetrexed per time, intra-venous drip, day 1.Treatment group was given 300 mg· m-2carboplatin per time, intravenous drip, day 1, on the basis of control group.Two groups were treated for more than 2 cycles with 21 days per cycle.The clinical efficacy, serum levels of carcino embryonic antigen ( CEA ), neuron-specific enolase (NSE) and cytokeratin antigen 19 (CYFRA21-1), and adverse drug reactions were com-pared between two groups.Results After treatment, total effective rates of treatment and control groups were 52.38%(22 cases /42 cases) and 42.86%(18 cases /42 cases) without significant difference (P>0.05).After treatment, the main indexes of treatment and control groups were compared : CEA were (37.53 ±6.28 ) and (39.15 ±5.80 ) ng· mL-1, NSE were (22.12 ±2.62 ) and (21.61 ±4.00 ) ng· mL-1, CYFRA21 -1 were ( 6.31 ±0.97 ) and (5.66 ±1.00)ng· mL-1, the differences were not statistically significant (all P>0.05).The adverse drug reactions of two groups were nausea , vomiting, myelosuppression , liver function damage , rash and fever.The total incidences of adverse drug reactions in treatment and control groups were 69.05%and 64.29% without significant difference (P>0.05).Conclusion The clinical efficacy and safety of pemetrexed injection combined with carboplatin injection in the treatment of advanced lung adenocarcinoma with EGFR -TKI resistance were equal to pemetrexed injection alone, and both could significantly inhibit the expressions of CEA , NSE and CYFRA21-1.
